title: Fingolimod and cardiac risk: latest findings and clinical implications.
abstract: Fingolimod is an oral medication approved for the treatment of relapsing multiple sclerosis (MS). It is unique compared with other approved disease-modifying therapies for MS in that it is the first oral agent and it has a novel mechanism of action. In clinical trials and postmarket use, it demonstrates clear therapeutic efficacy. However, it is associated with certain risks including cardiac concerns. The recent reports of cardiac events potentially associated with the drug prompted a regulatory agencies review of the use of fingolimod for MS in the USA and Europe. After completion of their review, the US Food and Drug Administration and the European Medicines Agency concluded that its benefits outweighed the risks. However, certain recommendations were made for appropriate patient selection for fingolimod and for more cautious first-dose monitoring. We review the use of fingolimod for MS in light of the recently reported potential cardiac risks. We conclude that with appropriate patient selection and careful monitoring, it appears to have a favorable benefits/risks profile and can be a valuable treatment option for relapsing MS. Continued postmarketing surveillance and data from the extension phase of its clinical trials will be very important in understanding the long-term efficacy and safety of fingolimod and to help determine its place in the treatment algorithm for multiple sclerosis.
authors.affiliation: Weill Cornell Medical College - Neurology, New York, NY, USA.
authors.forename: Wendy S
authors.initials: WS
authors.lastname: Vargas
authors.affiliation: Weill Cornell Medical College - Neurology, 1305 York Avenue, New York, NY 10021, USA.
authors.forename: Jai S
authors.initials: JS
authors.lastname: Perumal
keywords: bradycardia; cardiovascular risks; drug safety; fingolimod
references.citation: Expert Rev Clin Pharmacol. 2011 Sep;4(5):567-70
references.pmid: 22114884
references.citation: Ann Neurol. 2011 May;69(5):759-77
references.pmid: 21520239
references.citation: N Engl J Med. 2010 Feb 4;362(5):402-15
references.pmid: 20089954
references.citation: Nat Immunol. 2007 Dec;8(12):1295-301
references.pmid: 18026082
references.citation: Ther Adv Neurol Disord. 2012 Jul;5(4):205-20
references.pmid: 22783370
references.citation: Mult Scler. 2011 Nov;17(11):1387-9
references.pmid: 21652609
references.citation: Anesth Analg. 2004 Aug;99(2):623
references.pmid: 15271756
references.citation: Pflugers Arch. 1999 Oct;438(5):642-8
references.pmid: 10555561
references.citation: N Engl J Med. 2006 Sep 14;355(11):1124-40
references.pmid: 16971719
references.citation: Neurology. 2009 Jan 6;72(1):73-9
references.pmid: 19122034
references.citation: Mult Scler. 2012 Oct;18(10):1507-8
references.pmid: 22300970
references.citation: N Engl J Med. 2010 Feb 4;362(5):387-401
references.pmid: 20089952
references.citation: J Pharmacol Exp Ther. 2007 Nov;323(2):626-35
references.pmid: 17726159
references.citation: Curr Treat Options Neurol. 2012 Jun;14(3):256-63
references.pmid: 22426573
references.citation: Curr Opin Pharmacol. 2007 Apr;7(2):186-92
references.pmid: 17280869
references.citation: Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101
references.pmid: 20061941
references.citation: Discov Med. 2011 Sep;12(64):213-28
references.pmid: 21955849
references.citation: FASEB J. 2004 Mar;18(3):551-3
references.pmid: 14715694
references.citation: Trends Pharmacol Sci. 2003 Jan;24(1):2-4
references.pmid: 12498721
references.citation: Neurology. 2011 Feb 22;76(8 Suppl 3):S3-8
references.pmid: 21339489
references.citation: J Pharmacol Exp Ther. 2007 Nov;323(2):469-75
references.pmid: 17682127
references.citation: J Pharmacol Exp Ther. 2004 May;309(2):758-68
references.pmid: 14747617
references.citation: Nat Rev Mol Cell Biol. 2003 May;4(5):397-407
references.pmid: 12728273
references.citation: Nat Rev Immunol. 2008 Oct;8(10):753-63
references.pmid: 18787560
references.citation: J Clin Pharmacol. 2006 Aug;46(8):895-904
references.pmid: 16855074
references.citation: Mult Scler. 2010 Feb;16(2):197-207
references.pmid: 20028707
references.citation: Mult Scler Relat Disord. 2014 Sep;3(5):629-38
references.pmid: 26265275
references.citation: Mult Scler. 2013 Jan;19(1):126-8
references.pmid: 22729989
references.citation: Clin Neurol Neurosurg. 2010 Jun;112(5):365-85
references.pmid: 20362388
references.citation: Science. 1998 Mar 6;279(5356):1552-5
references.pmid: 9488656
references.citation: Curr Opin Pharmacol. 2006 Jun;6(3):244-50
references.pmid: 16563863
references.citation: Curr Opin Drug Discov Devel. 2010 Jul;13(4):481-8
references.pmid: 20597031
references.citation: Science. 2002 Apr 12;296(5566):346-9
references.pmid: 11923495
references.citation: Nature. 2004 Jan 22;427(6972):355-60
references.pmid: 14737169
references.citation: J Histochem Cytochem. 2002 May;50(5):661-70
references.pmid: 11967277
references.citation: Nature. 2009 Nov 5;462(7269):94-8
references.pmid: 19829296
references.citation: Br J Pharmacol. 2009 Nov;158(5):1173-82
references.pmid: 19814729
references.citation: Drug News Perspect. 2004 Jul-Aug;17(6):365-82
references.pmid: 15334188